Navigation Links
U.S. Patent Office Issues Notice of Allowance for Patent Application Related to CTI's GlycoPolymer Technology
Date:11/20/2011

SEATTLE, Nov. 21, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application directed to increasing the plasma half-life of therapeutic proteins and peptides by recombinantly conjugating them to a novel, non-immunogenic peptide repeat sequence. The patent and its related technology are exclusively licensed to Aequus Biopharma, Inc. (Aequus), a majority owned subsidiary of CTI, for the purpose of development and commercialization. The patent application entitled "Conjugates of biologically active proteins having a modified in vivo half-life" has also been filed in other regions and countries, including Europe and Japan. Corresponding patents have been granted in New Zealand, South Africa and Singapore.  

"This U.S. Patent Allowance is an important milestone for Aequus and its development of the GlycoPolymer technology," said Stewart D. Chipman, Ph.D., President and CSO of Aequus. "We believe that this technology has the potential to significantly streamline the development of first-in-class therapeutic proteins and peptides, as well as extend the half-life of existing therapeutic proteins and peptides to improve their therapeutic profile through less frequent dosing, resulting in improved patient compliance. Our lead program, AQB-101, is a novel glycoprotein with G-CSF-like activity that demonstrates an extended plasma half-life.  Aequus is currently generating in vivo data to demonstrate AQB-101's utility, and we look forward to further development of AQB-101 and the GlycoPolymer technology," Dr. Chipman concluded.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

About Aequus BioPharma, Inc.

Headquartered on Bainbridge Island, WA, Aequus BioPharma is a biopharmaceutical company committed to streamlining the development of biopharmaceuticals with improved pharmacokinetic properties in a wide variety of human disease indications. Aequus Biopharma is a majority owned subsidiary of Cell Therapeutics. For additional information, please visit www.aequusbiopharma.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of GlycoPolymer technology include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with  the GlycoPolymer technology in particular including, without limitation, the potential failure to prove safe and effective, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:

Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases
2. MedBox Develops Patent-Pending System for Storage and Retrieval of Prescription Drugs
3. RSB Spine, LLC, Announces European Patent Allowance
4. Awarepoint Advances Industry Leadership with New Patented Technology
5. Watson Confirms Exelon(R) Patent Challenge
6. Uroplasty Announces Issuance of New Apparatus Patent for the Urgent® PC Neuromodulation System Stimulator
7. Intellect Neurosciences Obtains Two New Patents in Japan for Its Alzheimers Immunotherapy Programs
8. Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimers Patent Application
9. Perrigo Confirms Filing for Testosterone Gel 1.0% and Announcement of Patent Infringement Lawsuit by Abbott
10. Regulus Therapeutics Expands Worldwide Patent Coverage on microRNA-122 to Treat Hepatitis C Virus (HCV) Infection
11. Life Spine Awarded Seven New Patents, Launches Six New Product Lines & Realizes 25% Sales Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... PLANO, Texas , April 20, 2017  Vivify ... via mobile devices, has been awarded a very significant ... care via EMRs to continual care via digital health. ... of key intellectual property and further secures Vivify,s position ... Vivify, launched in 2009, was the first company to ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce ... process has been in place since the RBMA was founded in 1968 with all ... Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... exposed to more adverse experiences than children in the general population. That’s because ... abuse, neglect or other family challenges. While no fault of their own, youth ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... of America (UCAOA) and College of Urgent Care Medicine will host industry leaders ... sessions and speakers will help those in the industry adapt to the issues ...
(Date:4/28/2017)... ... April 28, 2017 , ... People are starting to accept ... a hearing aid doesn’t have the stigma it had when great-grandpa wore his hearing ... Greater Boston, in a NALA North American Speaker Series (NASS) segment. “He ...
(Date:4/28/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a ... does not. Yisrayl says with so many titles and names for the Creator, it’s ... with a little Scripture, backed with a lot of research, the truth is undeniable. ...
Breaking Medicine News(10 mins):